Industry Dive’s Post

According to Simon Sinek, "Leadership is not about being in charge, it's about taking care of those in your charge." I feel that to my core and what makes being recognized by Pharmavoice100 as a Standout Leader particularly special. Check out the full list of my inspiring and talented industry peers below. It is wonderful to be sharing the honor with them all, especially those who I have met along my journey, such as Christine Sakdalan and Kristin Yarema, Ph.D. #Pharmavoice100 #lifesciences

#biopharma week in review: Did you miss it? #pharma strategy in hashtag #japan and beyond: Our experience suggests five building blocks and five focus areas that require the attention of the #CEOs and other business leaders across the industry to outperform the competition. #strategy #pharmaceuticalindustry #leadership #management #innovation #biotech #fda #oncology #drugdiscovery

Over the past year, I've had the privilege of attending numerous conferences and networking with investors and executives in the biotech industry. It's evident that securing funding in the current climate has been challenging. However, one consistent theme in my conversations with investors is the crucial importance of a strong and preferably experienced leadership team. Companies cannot just rely on exceptional science; they need the ability to articulate a commercial strategy, a clear vision, and strong operational expertise. This will make them attractive to investors looking for reliable and innovative partners in the high-risk biotech sector. A prime example is Third Arc Bio, which recently raised $165 million to develop oncology and autoimmune biologics. Their success can be attributed not only to their innovative science but also to their exceptional leadership team, led by former Johnson & Johnson executives. This underscores the critical role that experienced leadership plays in gaining investor confidence and driving biotech innovation forward. At GENerX Life, we are actively working with clients worldwide, coaching and advising on the leadership, skills, and competencies required to attract investment. Our expertise ensures that biotech companies are equipped with the right leaders and infrastructure to navigate today's competitive landscape. https://lnkd.in/eTi_TMyJ Visit us to learn more about our services - www.generx.life #Biotech #Leadership #Funding #Innovation #ExecutiveSearch #BiotechFunding #BusinessGrowth #GENerXLife #BiotechLeaders #Agileleaders

When you sit down with the CEO of FTSE giant AstraZeneca you don't expect to be talking about trips to Mars. But that's what we did, as he told me it's important to dream, to set big goals and to stretch yourself to achieve them. He's not actually going to Mars. I mean, are any of us?! We talked drug development too of course and whilst the sector goes crazy for obesity medication the real key to Astra's strategic success will be their cancer drugs. On leadership in the pharma sector, he says it's important to shape an organisation with common purpose, to believe in science and to invest in R&D. And it seems fending off a hostile takeover can be a great learning experience too. This is the latest edition of "The Leader" from Bloomberg News where we take a step back from the daily headlines to talk strategic vision, leadership, and as is turns out, space travel! #strategy #leadership #obesity #space https://lnkd.in/e28Q42Te

Two weeks to go until our webinar, where Hilary Beck (Eikon Therapeutics), Dean Phillips (Novartis Institute For Biomedical Research) and Susanne Wright (Apollo Therapeutics) will be sharing their advice and experience on running successful drug discovery teams. Have you registered yet? 👉 https://lnkd.in/e8pA3JcW Whether stepping into your first position in a drug discovery team, or an established leader interested in developing and improving your team's strategies, this webinar is for you. #DrugDiscovery #MedicinalChemistry #ScienceCareers #Leadership #Collaboration #Innovation

We are thrilled to present the second installment of Katie Litwin's series highlighting female executives in biotech! This edition features Krishna Allamneni, EVP & Chief Development Officer at Concarlo Therapeutics. Krishna shares her expert insights on navigating M&A activities, embracing remote work, and leveraging AI in drug development. Ready to gain valuable strategies and pioneering perspectives that are shaping the future of the industry? Read more NOW ➡ https://lnkd.in/gimuNJN4

Welcome to the newest episode of The Pharmaverse Podcast! Host Michael Pietrack interviews H. Jack West, MD, the VP of Clinical Development at Summit Therapeutics, Inc.. There is a lot of attention on Jack and Summit Therapeutics right now at the World Conference on Lung Cancer, as they share data on #ivonescimab. We are all anxious to it will live up to the hype of being "Ivon the Great!" In this discussion, Jack's takes us through his transition from practicing medicine to leading development in a pharmaceutical company. He siad, "Going into a pharma company is like riding a mechanical bull. The directions change frequently and sometimes you're not ready for them." Jack also shares his insights on leadership best practices and the top challenges facing the pharma industry. "Having well-defined roles and a clear value is important in leadership." The episode concludes with a discussion on Summit Therapeutics' recent positive press releases and Jack's social media presence.       Takeaways:  🤝Collaborations with pharma can be instrumental in making the leap from clinical practice to the pharmaceutical industry.  💹Transitioning from clinical practice to pharma requires a willingness to adapt to new priorities and challenges.  🕴Leadership in the pharmaceutical industry requires well-defined roles, clear value, and a culture of open communication and dissent.  💊The pharma industry faces challenges such as evolving regulatory approvals, acceptance of data from different regions, and incorporating patient perspectives.  🐟Working in a small pharma company offers agility, involvement in various processes, and the opportunity to make a significant impact.  👐Stay open to new perspectives and be willing to modify your opinions based on new information.  🩺Adapt to the evolving regulatory landscape and consider the challenges of generalizing data from different regions.  🏥Recognize the changing role of patients in decision-making and incorporate their perspectives and priorities.  💉Embrace the opportunities for growth and learning in a small company environment.  💊Be bold, clarify your goals, and actively pursue your desired path.     Chapters  00:00 Introduction and Background  03:08 Transitioning from Clinical Practice to Pharma  10:45 Leadership Best Practices in the Pharma Industry  18:03 Challenges Facing the Pharma Universe  28:00 The Rewards of Working in a Small Pharma Company  36:12 Summit Therapeutics' Positive Press Releases  37:03 https://lnkd.in/gd5Hmeqr

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down: Ken Song Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and then a $4.1 billion exit to Bristol Myers Squibb just months after that Nasdaq debut. Now, he’s founder, chair and CEO of a new biotech called Candid Therapeutics, according to his LinkedIn. The roles started in May, according to his profile on the job networking site. The company is working on biologics in the autoimmune field, according to a job posting. With about two decades of leadership experience at biotech startups, a diagnostics company and a healthcare VC firm, Song is ready for his next post. “I’ve actually been looking at quite a few things already. I love that part of just building and pursuing innovation,” Song told Endpoints News in early March. “I’m usually not one to sit idle, so I have been looking at a fair number of different potential interesting opportunities on the company side. I’m unlikely to go back to being an investor.” It’s unclear who is funding Candid at this time. The RayzeBio deal led to a big payday for Song. The cash value of shares he and his family trust beneficially owned came out to $101 million, according to an SEC filing on Bristol Myers’ tender offer. He also had about $70 million in cash value from “in-the-money options,” according to the paperwork. — Kyle LaHucik Ray Deshaies → Amgen SVP of global research Ray Deshaies wrote on LinkedIn that Angela Coxon will take over his role on an interim basis. Coxon has been with Amgen since 1999 and spent the last three years as VP of discovery oncology research. In his LinkedIn post, Deshaies touched on some of the molecules that defined his tenure: the KRAS G12C drug sotorasib (now marketed as Lumakras), the obesity candidate MariTide and the siRNA heart drug olpasiran, among others. “Stepping down from my leadership role has led me to reflect on my time at Amgen over the past 7 years. This reflection has triggered two emotions: gratitude and pride,” he said. “It has been a tremendous privilege to have such an awesome set of colleagues as I have been blessed with at Amgen. It has been an experience — and opportunity — of a lifetime.” Eric Cox → As momentum builds with its Boehringer Ingelheim-partnered weight loss drugs, Zealand Pharma has selected Eric Cox as chief commercial officer. He begins on Aug. 5 and comes from Carmot Therapeutics, where he was VP, commercial strategy and business development. Roche’s $2.7 billion deal for Carmot is off to an auspicious start with early readouts for two obesity drugs, CT-388 and CT-996. Cox had a 16-year career with Merck before his appointment at AstraZeneca… #lucidquest #genetherapy #celltherapy

Kudos to Debiopharm! But the problem of silos remains, certainly in big companies. IMHO, the root cause has to do with communication between different stakeholders, at the very basic level of the words that are being used. They are either imprecise and ambiguous ( e.g. "inflammation" ") and/or mean different things to different stakeholders (ask a clinical oncologist, a GP or a cancer biologist to give you a clear definition of "cancer"). When different experts meet to discuss, they may use the same words but the meaning is not the same. There is a disconnect.... and no one is truly aware of it... This leads to quid pro quos, silos and sometimes catastrophic outcomes. I have seen it over and over again in my 20 years of teaching biotech to all non-biologists... A standardized, controlled vocabulary, or ontology, is crucial to ensure clear communication and collaboration across all functions. I have nailed it down, at least version 1.0, thanks to my 3000 students representing all functions in the pharma industry. I'd love to publish what I have as an online interactive glossary where each term becomes an item of actionable knowledge. But I need help and some funding. Anyone out there interested?

Anil Kane, Ph.D., MBA, executive director and global head of technical and scientific affairs at Thermo Fisher Scientific, recently spoke with Global Business Reports (GBR) about how #CDMOs are playing an increasingly important role in the development and commercialization of lifesaving therapies. He explains how CDMOs today must deliver transformational value: with access to cutting-edge technologies and advanced materials, data-driven insights, innovative manufacturing processes and skilled, specialized workers. Read Anil’s insights to learn more about how the relationship between CDMOs and #pharma has evolved – and what’s on the horizon for the industry in 2024 and beyond: http://spr.ly/6047dzU47